Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06600581 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness
A Phase 2 study of Sarcopenic Obesity and Muscle Performance, sponsored by Immunis.
- Active
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 4
- Study locations
NCT06600581 is a Phase 2 study of Sarcopenic Obesity and Muscle Performance that is active but no longer recruiting, run by Immunis. The registered enrollment target is 55 participants. The trial reports 4 study locations across 2 states.
The verdict
NCT06600581, a Phase 2 study of Sarcopenic Obesity and Muscle Performance, is active but no longer recruiting, sponsored by Immunis.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 4
- Study locations
Study Summary
Placebo controlled study for safety and efficacy of IMM01-STEM on muscle performance in seniors with obesity and muscle weakness
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL IMM01-STEM
- BIOLOGICAL IMM01-STEM alternating with placebo (saline)
Study Locations (4)
California
- National Institute of Clinical Research (NICR) - Garden Grove
- National Institute of Clinical Research (NICR) - Pomona
Kansas
- Johnson Country Clinical Trials (JCCT) - Lenexa
- Tekton Research - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2024-12-19 |
| Est. Completion | 2026-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06600581
The ClinicalTrials.gov registry entry for NCT06600581 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunis, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sarcopenic Obesity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06600581 reports 4 study locations spanning 2 distinct geographic areas - top geographies include California, Kansas.
Frequently Asked Questions
What is clinical trial NCT06600581 about?
NCT06600581 is a clinical study titled "Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness". Placebo controlled study for safety and efficacy of IMM01-STEM on muscle performance in seniors with obesity and muscle weakness
What is the current status of trial NCT06600581?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2024-12-19. Estimated completion is 2026-12-15.
What conditions does trial NCT06600581 study?
This clinical trial studies the following conditions: Sarcopenic Obesity, Muscle Performance.
What interventions are being tested in trial NCT06600581?
The interventions under investigation include: Placebo (OTHER), IMM01-STEM (BIOLOGICAL), IMM01-STEM alternating with placebo (saline) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06600581?
This trial is sponsored by Immunis, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06600581 being conducted?
This trial has 4 study locations across California, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcopenic Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.